Trial reportAJR. American journal of roentgenology2022
Strategies for Reducing False-Positive Screening Results for Intermediate-Size Nodules Evaluated Using Lung-RADS: A Secondary Analysis of National Lung Screening Trial Data.
Trial report in AJR. American journal of roentgenology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Evaluating Korean Lung-RADS Category 2b: Diagnostic Performance and Interreader Agreement in Lung Cancer Screening.Journal of Korean medical science · 2026Article
- Training set augmentation and biology-aware harmonization improve radiomic models for lung cancer prediction in indeterminate nodules.Scientific reports · 2026Article
- Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening.Thorax · 2025Observational
- Comparison of Lung-RADS Version 2022 and British Thoracic Society Guidelines in Classifying Solid Pulmonary Nodules Detected at Lung Cancer Screening CT.Life (Basel, Switzerland) · 2024Article
- Risk of Lung Cancer in Peripheral Pulmonary Nodules.Academic radiology · 2024Article
- Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial.The Lancet regional health. Europe · 2024Article
- Impact of annual trend volume of low-dose computed tomography for lung cancer screening on overdiagnosis, overmanagement, and gender disparities.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura at Low-Dose CT for Lung Cancer Screening.Radiology · 2024Article
- Analysis of the correlation between clinical and imaging features of malignant lung nodules and pathological types.Frontiers in surgery · 2023Article
- Quantitative parameters of enhanced dual-energy computed tomography for differentiating lung cancers from benign lesions in solid pulmonary nodules.Frontiers in oncology · 2022Article
- Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening.Current problems in diagnostic radiologyArticle
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.